Literature DB >> 12783596

Novel pharmacological approaches in the treatment of breast cancer.

Rita Nahta1, Gabriel N Hortobagyi, Francisco J Esteva.   

Abstract

Breast cancer is the most common malignancy among women. Novel pharmacological agents, including hormonal, cytotoxic and biological therapies, are currently being developed and tested in clinical trials and may offer patients more treatment options and an improved chance of long-term survival. Signal transduction inhibitors that block endocrine or growth factor pathways have demonstrated exciting antitumour effects in clinical trials. In addition to new chemotherapeutic drugs, numerous biological agents including growth factor receptor-directed monoclonal antibodies and tyrosine kinase inhibitors that target specific molecular lesions are being examined as potential breast cancer treatments.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12783596     DOI: 10.1517/13543784.12.6.909

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  2 in total

1.  A novel, broad-spectrum anticancer compound containing the imidazo[4,5-e][1,3]diazepine ring system.

Authors:  Min Xie; Ravi K Ujjinamatada; Mariola Sadowska; Rena G Lapidus; Martin J Edelman; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2010-06-15       Impact factor: 2.823

2.  Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells.

Authors:  Massimiliano Salerno; Diane Palmieri; Amina Bouadis; Douglas Halverson; Patricia S Steeg
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.